A new preprint study from Kaiser Permanente Northwest found a ~1/1860 and ~1/2650 risk of myopericarditis in males age 18-24 and 12-17 respectively following a 2nd dose of COVID-19 mRNA vaccine.
“We assembled a cohort 12 to 39 years old patients, insured by Kaiser Permanente Northwest, who received at least one dose of an mRNA vaccine (Pfizer BioNTech or Moderna) between December 2020 and October 2021. We followed them for up to 30 days after their second dose of an mRNA vaccine to identify encounters for myocarditis, pericarditis or myopericarditis.
We identified additional valid cases of myopericarditis following an mRNA vaccination that would be missed by the VSDs search algorithm, which depends on select hospital discharge diagnosis codes. The true incidence of myopericarditis is markedly higher than the incidence reported to US advisory committees.”2021.12.21.21268209v1.full_
FDA Authorizes Emergency Use of Pfizer COVID-19 Vaccine Booster Shot for Kids as Young as 12
The U.S. FDA on Monday (Jan. 3) extended the emergency use authorization for the Pfizer COVID-19 booster shot to include kids aged 12 to 15, paving the way for them to be eligible for the jabs later this week.
It is the first booster shot to receive emergency authorization for this age group and it only applies to the Pfizer COVID-19 vaccine.
However, there are still many outstanding questions about the risk of myocarditis, myopericarditis and pericarditis — inflammation of the heart and tissue surrounding the heart—that may be caused in this age group after receiving a COVID-19 booster shot.
No clinical trials are cited in the FDA press release .